How N.J. company, Tris Pharma, is working to solve severe shortage of ADHD medication

Company says Dyanavel, substitutable by prescribers, is available in direct-to-patient program — and that there’s no shortage of supply

A year-long shortage of ADHD medicine has created an endless loop of millions of parents searching desperately to find medication for their kids — often on a monthly basis.

Monmouth Junction-based Tris Pharma is working to help.

Tris Pharma and Perigon Pharmacy 360 recently announced a partnership to make Dyanavel XR, an amphetamine medicine for attention deficit hyperactivity disorder, more readily available to patients nationwide.

Together, Tris Pharma and Perigon launched a direct-to-patient program, Dyanavel Delivered, that allows patients and caregivers to seamlessly access Dyanavel XR extended-release tablets through Perigon’s digital pharmacy, enhance their medication management and receive reimbursement assistance and support to help navigate their treatment journey while reducing administrative burden for both patients and providers.

Dyanavel XR is indicated for the treatment of ADHD in patients 6 years and older.

The program is available across the U.S. (For more information, click here.)

Please note: You will need a new prescription.

Tris Pharma officials said Dynavel is a unique branded product that is therapeutically equivalent to and substitutable by the prescriber for amphetamines, but since it has a distinctive delivery mechanism, it is not substitutable by a pharmacist as a generic, and the patient will need a new prescription sent to Perigon Pharmacy 360.

The good news: There is no shortage of supply. Tris Pharma is among the relatively few companies that have managed to not only maintain, but increase supply of ADHD medicines without interruption.

Ketan Mehta, the founder and CEO of Tris Pharma, said the company is glad to be able to fill a need — potentially for desperate parents.

“This partnership underscores our continued commitment to ensuring patients have access to the medications they need to treat their ADHD symptoms,” he said. “In an environment where shortages have been significant and widespread for more than a year, Tris Pharma is among the relatively few companies that have managed to not only maintain but increase supply of our ADHD medications without interruption.

About Tris Pharma

Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain and neurological disorders, including addiction and diseases of the central nervous system. Tris is an established commercial organization with a robust portfolio of best-in-class ADHD products and a promising pipeline of differentiated, near-term drug candidates.

“Our program with Perigon builds on this success by offering patients a more convenient way to consistently obtain access to their Dyanavel XR extended-release tablet prescription.”

The need certainly is there. An estimated 14 million Americans need the medication, which can only be filled one month at a time.

Since the November 2021 approval of Dyanavel XR extended-release tablets, Tris Pharma has seen a consistent increase in prescription volume and taken steps to manage manufacturing volume to ensure that the company is able to consistently meet and exceed demand.

Ted Mills, CEO at Pennsylvania-based Perigon Pharmacy 360, said his company has been eager to partner with Tris Pharma.

“We’re incredibly excited to partner with Tris Pharma on this program, because we believe it has the potential to enhance quality of care and reduce prescription access challenges for ADHD patients during a particularly critical time,” he said. “Additionally, this partnership will provide important insights about the impact of innovative technology and advanced health care solutions on real-world patient outcomes.”